Form 483

The Richline Group Inc Form 483, 2016-11-03

FDA issued a Form 483 to The Richline Group Inc on 2016-11-03 with 6 public-safe observations.

483· Form 483 issuedHuman Drugs6 observations

The Richline Group Inc · Tamarac, United States · Issued November 3, 2016

Overview

  • 6 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

3 Nov 2016
21 CFR 211.113(a)

Procedures for non-sterile drug products

Cited by Jennifer Lalama

3 Nov 2016
21 CFR 211.186(a)

Written procedures followed

Cited by Jennifer Lalama

3 Nov 2016
21 CFR 211.188

Prepared for each batch, include complete information

Cited by Jennifer Lalama

3 Nov 2016
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Jennifer Lalama

3 Nov 2016
21 CFR 211.63

Equipment Design, Size and Location

Cited by Jennifer Lalama

Inspected site

TRThe Richline Group IncTamarac, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(a)Cited across public-safe Form 483 observations1x
21 CFR 211.186(a)Cited across public-safe Form 483 observations1x
21 CFR 211.188Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.63Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 6 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere